Clinical trial · Observational
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2Bio) Gene Therapy (GT) Products
NCT06885424CI-TRIAL-00112235DESCENT-1enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Conditions
Conditions (15)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Carcinoma | Colorectal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Carcinoma (CRC) | Colorectal Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Head and Neck (HNSCC) | Head and Neck Squamous Cell Carcinoma | ALIAS | 0.85 |
| Mesothelioma | Malignant Mesothelioma | CURATED_EXACT | 0.92 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No additional intervention administered in this long term follow-up study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants that received A2 Bio GT products
- interventionNames
- Other: No additional intervention administered in this long term follow-up study
Primary outcomes (1)
- measure
- Long-term safety of previous A2 Bio GT treatment
- timeFrame
- 15 years post treatment with A2 Bio GT product
- description
- Long-term safety of previous A2 Bio GT treatment as determined by incidence of adverse events (AEs)
Secondary outcomes (4)
- measure
- Overall survival
- timeFrame
- 15 years post treatment with A2 Bio GT product
- description
- The time from dosing of A2 Bio GT product to the date of death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study 2. Able to provide written informed consent for this long-term follow-up study 3. Able to comply with study requirements Exclusion Criteria: 1\. There are no specific exclusion criteria for this study
References
Publications (0)
Data not yet available
No reference posted for this study.